Search
Now showing items 1-3 of 3
In honour of Professor Jackie Ying, recipient of the Journal of Drug Targeting's Lifetime Achievement Award�for 2020
(
Taylor and Francis Ltd
, 2020 , Article)
[No abstract available]
Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
(
Taylor and Francis Ltd
, 2020 , Article)
Objectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize ...
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
(
Taylor and Francis Ltd
, 2020 , Article Review)
The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2 that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE inhibitors (ACEIs) and angiotensin-II receptor ...